CTOR (Citius Oncology) Dividend Payout Ratio : 0.00 (As of Sep. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Dividend Payout Ratio?

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Citius Oncology's Dividend Payout Ratio for the months ended in Sep. 2023 was 0.00.

The historical rank and industry rank for Citius Oncology's Dividend Payout Ratio or its related term are showing as below:

CTOR's Dividend Payout Ratio is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.37
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-12-15), the Dividend Yield % of Citius Oncology is 0.00%.

Citius Oncology's Dividends per Share for the months ended in Sep. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Citius Oncology Dividend Payout Ratio Historical Data

The historical data trend for Citius Oncology's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Dividend Payout Ratio Chart

Citius Oncology Annual Data

Trend

Sep22

Dividend Payout Ratio

Citius Oncology Semi-Annual Data
	Sep22	Sep23
Dividend Payout Ratio	-	-

Competitive Comparison of Citius Oncology's Dividend Payout Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citius Oncology's Dividend Payout Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Citius Oncology's Dividend Payout Ratio falls into.

Citius Oncology Dividend Payout Ratio Calculation

Citius Oncology's Dividend Payout Ratio for the fiscal year that ended in Sep. 2022 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Sep. 2022 )	/	EPS without NRI (A: Sep. 2022 )
	=	0	/	-0.076
	=	N/A

Citius Oncology's Dividend Payout Ratio for the quarter that ended in Sep. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2023 )	/	EPS without NRI (Q: Sep. 2023 )
	=	0	/	-0.178
	=	N/A

Citius Oncology (NAS:CTOR) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Citius Oncology Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Citius Oncology's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Citius Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Ave, Suite 2446, New York, NY, USA, 10170

Website

Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.